These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36397383)

  • 41. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Hernandez L; Kuwabara H; Shah A; Yamabe K; Burnett H; Fahrbach K; Koufopoulou M; Iwakiri R
    Pharmacoeconomics; 2020 Jan; 38(1):69-84. PubMed ID: 31552601
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.
    Dulai PS; Battat R; Barsky M; Nguyen NH; Ma C; Narula N; Mosli M; Vande Casteele N; Boland BS; Prokop L; Murad MH; D'Haens G; Feagan BG; Sandborn WJ; Jairath V; Singh S
    Am J Gastroenterol; 2020 Jun; 115(6):885-894. PubMed ID: 32384283
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis.
    Taxonera C; Olivares D; López-García ON; Alba C
    Aliment Pharmacol Ther; 2023 Mar; 57(6):610-619. PubMed ID: 36645145
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
    Vickers AD; Ainsworth C; Mody R; Bergman A; Ling CS; Medjedovic J; Smyth M
    PLoS One; 2016; 11(10):e0165435. PubMed ID: 27776175
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
    Panés J; Vermeire S; Lindsay JO; Sands BE; Su C; Friedman G; Zhang H; Yarlas A; Bayliss M; Maher S; Cappelleri JC; Bushmakin AG; Rubin DT
    J Crohns Colitis; 2018 Jan; 12(2):145-156. PubMed ID: 29028981
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
    Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
    Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries.
    Armuzzi A; Hart A; Cappelleri JC; Mammar N; Hur P; Hoskin B; Hennessy F; Milligan G; Dignass A
    BMC Gastroenterol; 2023 Jan; 23(1):17. PubMed ID: 36658481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy.
    Iizuka M; Etou T; Sagara S
    World J Gastroenterol; 2022 Sep; 28(34):4959-4972. PubMed ID: 36160647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of biological interventions for ulcerative colitis on health-related quality of life.
    LeBlanc K; Mosli MH; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study.
    Kwon Y; Kim ES; Choe YH; Kim MJ
    World J Gastroenterol; 2022 Jul; 28(28):3666-3681. PubMed ID: 36161040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two cases in which tofacitinib effectively treated both ulcerative colitis and alopecia areata.
    Kikuchi O; Saito D; Miura M; Wada H; Ozaki R; Tokunaga S; Minowa S; Fukuyama M; Mitsui T; Sakuraba A; Hayashida M; Miyoshi J; Matsuura M; Ohyama M; Hisamatsu T
    Clin J Gastroenterol; 2020 Oct; 13(5):788-793. PubMed ID: 32592149
    [TBL] [Abstract][Full Text] [Related]  

  • 52. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
    Dhaliwal J; McKay HE; Deslandres C; Debruyn J; Wine E; Wu A; Huynh H; Carman N; Crowley E; Church PC; Walters TD; Ricciuto A; Griffiths AM;
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1300-1308. PubMed ID: 33909911
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis.
    Suzuki Y; Watanabe M; Matsui T; Motoya S; Hisamatsu T; Yuasa H; Tabira J; Isogawa N; Tsuchiwata S; Arai S; Hibi T
    Inflamm Intest Dis; 2019 Oct; 4(4):131-143. PubMed ID: 31768386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful initial tofacitinib treatment for acute severe ulcerative colitis with steroid resistance: a case series.
    Komeda Y; Kono M; Kashida H; Tribonias G; Masaki S; Takada R; Nagai T; Hagiwara S; Nishida N; Takenaka M; Honjo H; Matsui S; Tsuji N; Kudo M
    Ann Gastroenterol; 2023; 36(1):97-102. PubMed ID: 36593812
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis.
    Schultz BG; Diakite I; Carter JA; Snedecor SJ; Turpin R
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1592-1600. PubMed ID: 34714104
    [No Abstract]   [Full Text] [Related]  

  • 56. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies.
    Motoya S; Watanabe M; Kim HJ; Kim YH; Han DS; Yuasa H; Tabira J; Isogawa N; Arai S; Kawaguchi I; Hibi T
    Intest Res; 2018 Apr; 16(2):233-245. PubMed ID: 29743836
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
    Chaparro M; Garre A; Mesonero F; Rodríguez C; Barreiro-de Acosta M; Martínez-Cadilla J; Arroyo MT; Manceñido N; Sierra-Ausín M; Vera-Mendoza I; Casanova MJ; Nos P; González-Muñoza C; Martínez T; Boscá-Watts M; Calafat M; Busquets D; Girona E; Llaó J; Martín-Arranz MD; Piqueras M; Ramos L; Surís G; Bermejo F; Carbajo AY; Casas-Deza D; Fernández-Clotet A; García MJ; Ginard D; Gutiérrez-Casbas A; Hernández L; Lucendo AJ; Márquez L; Merino-Ochoa O; Rancel FJ; Taxonera C; López Sanromán A; Rubio S; Domènech E; Gisbert JP
    J Crohns Colitis; 2021 Jan; 15(1):35-42. PubMed ID: 32969471
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States.
    Hong SJ; Krugliak Cleveland N; Akiyama S; Zullow S; Yi Y; Shaffer SR; Malter LB; Axelrad JE; Chang S; Hudesman DP; Rubin DT
    Crohns Colitis 360; 2021 Jan; 3(1):otab002. PubMed ID: 36777067
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience.
    Kotwani P; Terdiman J; Lewin S
    J Crohns Colitis; 2020 Jul; 14(7):1026-1028. PubMed ID: 32020189
    [TBL] [Abstract][Full Text] [Related]  

  • 60. REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study.
    Ma C; Panaccione R; Xiao Y; Khandelwal Y; Murthy SK; Wong ECL; Narula N; Tsai C; Peerani F; Reise-Filteau M; Bressler B; Starkey SY; Loomes D; Sedano R; Jairath V; Bessissow T;
    Am J Gastroenterol; 2023 May; 118(5):861-871. PubMed ID: 36580497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.